Ausgabe 3/2021
Inhalt (14 Artikel)
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review
Maria Carolina Stipp, Alexandra Acco
The use of zebrafish model in prostate cancer therapeutic development and discovery
Haneen Amawi, Alaa A. A. Aljabali, Sai H. S. Boddu, Sadam Amawi, Mohammad A. Obeid, Charles R. Ashby Jr., Amit K. Tiwari
Irinotecan-induced intestinal mucositis in mice: a histopathological study
Thaise Boeing, Marcelo Biondaro Gois, Priscila de Souza, Lincon Bordignon Somensi, Débora de Mello Gonçales Sant´Ana, Luisa Mota da Silva
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
Haeseong Park, Kerry Williams, Nikolaos A. Trikalinos, Sarah Larson, Benjamin Tan, Saiama Waqar, Rama Suresh, Daniel Morgensztern, Brian A. Van Tine, Ramaswamy Govindan, Jingqin Luo, A. Craig Lockhart, Andrea Wang-Gillam
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects
X. Zhu, Y. Ding, Y. Yu, M. Wang, W. Zhou, J. Wang, X. Zhu, H. Zhang, M. Wang, K. Chai, X. Zhang, A. Luk, W. Jiang, S. Liu, Q. Zhang
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
Madusha Meemanage, Lindsay C. Spender, Diane Collinson, Joanna Iannetta, Pranavi Challapalli, Julie Turbitt, Caroline Clark, Mark Baxter, Graeme Murray, Shaun Walsh, Zofia Miedzybrodzka, Russell D. Petty
Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia
Abrar Al-Sheikh, Al-Motassem Yousef, Daniah Alshamaseen, Rand Farhad
A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
Rui Chen, Hongyun Wang, Wen Zhong, Salvatore Chessari, Corinna Lanzarotti, Alberto Bernareggi, Pei Hu
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
Kumiko Umemoto, Hideaki Takahashi, Chigusa Morizane, Ikuhiro Yamada, Satoshi Shimizu, Kazuhiko Shioji, Yukio Yoshida, Masayo Motoya, Nobumasa Mizuno, Yasushi Kojima, Takeshi Terashima, Kazuhiro Uesugi, Makoto Ueno, Junji Furuse, Tetsuo Akimoto, Masafumi Ikeda
FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway
Ya-Kun Liu, Ya-Jing Jia, Shi-Hao Liu, Jing Ma
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer
Shuang Liu, Shoujing Zhao, Yang Dong, Tingting Wang, Xiaojia Niu, Lijing Zhao, Guan Wang
Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation
Chuan-Kun Shan, Yi-Bo Du, Xiao-Tian Zhai, Yue-Xuan Wang, Yi Li, Jian-Hua Gong, Zhi-Juan Ge, Xiu-Jun Liu, Yong-Su Zhen
BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series
Sabeeh-ur-Rehman Butt, Alberto Mejias, Cristina Morelli, Gonzalo Torga, Marlene Happe, Anna Patrikidou, Hendrik-Tobias Arkenau